Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Board Changes

16th Sep 2009 07:01

RNS Number : 1250Z
TyraTech, Inc.
16 September 2009
 



For immediate release

16 September 2009

TYRATECH, INC.

("TyraTech" or "the Company")

Board Changes

TyraTech, Inc. (AIM: TYR), a leading independent novel eco-technology company for human, animal and environmental health, is pleased to announce that Patrick Regan will join the Board as a Non-Executive Director and that David Paul Szostak will step down from the Board as Non-Executive Director. Mr Szostak joined the Board in April 2008 to represent XL TechGroup and will now step down from the BoardBoth changes take place with immediate effect

Mr Regan thirty seven joins the Board as a representative of the Laurus-Valens Group, the parent Group of PetroTech Holdings Corporation, which has a 45.69% shareholding in TyraTech. He brings to the Board over sixteen years of financial analysis, corporate management, investment banking and venture capital experience gained in the USMr Regan habeen a senior managing director for Laurus Capital Management LLC since 2001 and has also served the same role at Valens Capital Management LLC since its establishment in 2007. 

In addition to his fund management experience at Laurus-Valens, hhas spent four years as a financial analyst at Geller & Company, a financial services accounting firm, primarily providing CFO functions to private companies and financial planning for high net worth individuals. At Geller, he was involved in private placement financing, management consulting and general corporate finance functions. Between 1999 and 2001, Patrick Regan was an associate at Tower Hill Capital Group, an investment banking boutique and venture capital firm.

Mr Regan has a Bachelor of Science in Business and Economics from Lehigh University and an MBA from Fordham University. 

Mr. Regan has no other previous or current Directorships. 

There are no further details required to be disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules.

Commenting on the board changes Geoffrey Vernon, Chairman of TyraTech, said:

"I am delighted to welcome Patrick Regan to the Board as he brings a wealth of experience of matters across a range of different areas important to TyraTech. His understanding of the financial dynamics of small cap companies and his investment banking and venture capital experience will be beneficial to the Group."

"I would like to express my sincere gratitude to David for his experience and expertise throughout his time at TyraTech and wish him well for the future. His contribution has been highly valuable."

For further information please contact:

For further information please contact:

TyraTech Inc.

Douglas Armstrong Ph.D., Chief Executive Officer +1 (321) 409 7723

Keith Bigsby, Chief Financial Officer +1 (321) 409 7714

www.tyratech.com

Nomura Code Securities

Charles Walker/Clare Terlouw +44 (0)20 7776 1200

www.nomuracode.com

Buchanan Communications

Mary-Janeߛ Elliott / Lisa Baderoon +44 (0)20 7466 5000 / Catherine Breen / Stasa Filiplic

www.buchanan.uk.com

About TyraTech

TyraTech was formed in 2004 to develop and commercialise products for the control of invertebrate pests and pathogens using the Company's proprietary technology. TyraTech, which already has products on the market, is positioned for human health, animal health and pesticide market opportunities which total over $32 billion globally. TyraTech's Nature's Technology provides the Company with a wide variety of product and business opportunities in many markets and geographic regions. The differentiating feature of these products is the potential to have a combined level of potency and safety that other invertebrate control products are unable to offer. TyraTech's platform brings many of the principles of drug discovery and development to the fields of insecticides and parasiticides. By targeting specific chemoreceptors that are found in invertebrates but not in humans and animals, TyraTech can produce products that use natural plant derived compounds targeting these receptors.

TyraTech's plan for the use of its technology is to develop selected proprietary active ingredients which can then be used across a wide variety of market segments, either by development partners or by TyraTech itself. TyraTech already has products or partnerships in the areas of professional and horticultural insect control, and for consumer and professional pest control. TyraTech also has an innovative partnership with Kraft to use its natural oils to develop functional foods for improving the health of the more than 2 billion people worldwide subject to intestinal parasitic infections.

TyraTech also has a separate technology with associated intellectual property that is the basis for the Sustainable Solutions business. This technology has been incorporated into specialised dairy farm equipment for processing cattle manure waste to a usable material for TyraTech to sell as a commercial plant growing medium. For more information please visit www.tyratech.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAMGGMLMKGGLZZ

Related Shares:

Tyratech
FTSE 100 Latest
Value8,809.74
Change53.53